[Inhaled budesonide for chronic obstructive pulmonary disease]

Area of Science:

• Pulmonology
• Pharmacology

Background:

• Corticosteroids offer benefits for some chronic obstructive pulmonary disease (COPD) patients, but side effects are a concern.
• Inhaled corticosteroids represent a safer long-term treatment option for COPD management.
• Identifying COPD patients who benefit from steroids is crucial for personalized treatment.

Purpose of the Study:

• To investigate the efficacy of inhaled budesonide in improving clinical symptoms and pulmonary function in stable COPD patients.
• To determine if response to a B2-agonist can predict steroid responsiveness in COPD.
• To assess the impact of inhaled budesonide on the need for supplemental bronchodilator use.

Main Methods:

• A double-blind, placebo-controlled crossover trial involving 44 stable COPD patients.
• Patients received either 800 micrograms/day of inhaled budesonide or a placebo for 6 weeks, with a 4-week washout period.
• Pulmonary function (FEV1) and B2-agonist use were monitored.

Main Results:

• Significant improvement in FEV1 (>20%) was observed in 33 out of 42 B2-agonist responders treated with budesonide compared to placebo.
• A significant reduction in the mean number of B2-agonist inhalations was noted during budesonide treatment.
• Approximately 75% of COPD patients showed improved spirometry and reduced bronchodilator consumption with inhaled steroids.

Conclusions:

• Inhaled budesonide effectively improves spirometry and reduces the need for rescue bronchodilators in a significant proportion of stable COPD patients.
• Responsiveness to bronchodilators may help identify COPD patients who are likely to benefit from inhaled corticosteroid therapy.
• Inhaled corticosteroids are a valuable therapeutic option for managing stable COPD, offering benefits with a favorable safety profile.